Literature DB >> 12473843

Prevalence of hepatitis C virus infection and risk for hepatocellular carcinoma and non-Hodgkin lymphoma in AIDS.

Eric A Engels1, Morten Frisch, Jay H Lubin, Mitchell H Gail, Robert J Biggar, James J Goedert.   

Abstract

Hepatitis C virus (HCV) infection is highly prevalent in some subpopulations with AIDS. HCV is linked to hepatocellular carcinoma (HCC) and possibly non-Hodgkin lymphoma (NHL), but the impact of AIDS on these associations is uncertain. We used U.S. registry data to study HCC and NHL risk in 304,411 adults with AIDS, comparing cohort subgroups with high prevalence (hemophiliacs and injection drug users) or low prevalence (homosexual men, heterosexuals, and others) of HCV infection. The ratio of observed to expected cancer cases (standardized incidence ratio [SIR]) measured risk relative to the general population. Sixty-one HCC cases were observed (SIR, 7.5; 95% confidence interval, 5.7-9.6). Risk for HCC was higher in subgroups with high prevalence of HCV infection than in subgroups with low prevalence of HCV infection (SIR: 11.4 versus 5.5, respectively; p =.004). Subjects developed the following NHL grades: low, 35 cases; intermediate, 1035 cases; high, 784 cases; and unspecified, 1395 cases. For each NHL grade, SIRs were highest in subgroups with low prevalence of HCV infection. These data suggest an effect of HCV infection on HCC risk among adults with AIDS. On the other hand, NHL risk was not higher for groups in whom HCV infection was prevalent.

Entities:  

Mesh:

Year:  2002        PMID: 12473843     DOI: 10.1097/00126334-200212150-00012

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  9 in total

1.  The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States.

Authors:  Vikrant V Sahasrabuddhe; Meredith S Shiels; Katherine A McGlynn; Eric A Engels
Journal:  Cancer       Date:  2012-06-26       Impact factor: 6.860

2.  Moving forward in HIV-associated cancer.

Authors:  Satish Gopal; Chad J Achenbach; Elizabeth L Yanik; Dirk P Dittmer; Joseph J Eron; Eric A Engels
Journal:  J Clin Oncol       Date:  2014-02-18       Impact factor: 44.544

3.  Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study.

Authors:  Todd M Gibson; Lindsay M Morton; Meredith S Shiels; Christina A Clarke; Eric A Engels
Journal:  AIDS       Date:  2014-09-24       Impact factor: 4.177

4.  Hepatocellular carcinoma in African Blacks: Recent progress in etiology and pathogenesis.

Authors:  Michael C Kew
Journal:  World J Hepatol       Date:  2010-02-27

5.  Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation.

Authors:  Christopher J Hoffmann; Aruna K Subramanian; Andrew M Cameron; Eric A Engels
Journal:  Transplantation       Date:  2008-09-27       Impact factor: 4.939

6.  Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients.

Authors:  Lindsay M Morton; Ola Landgren; Nilanjan Chatterjee; David Castenson; Ruth Parsons; Robert N Hoover; Eric A Engels
Journal:  Blood       Date:  2007-09-12       Impact factor: 22.113

Review 7.  Non-AIDS-defining malignancies in HIV-infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities.

Authors:  Eric A Engels
Journal:  AIDS       Date:  2009-05-15       Impact factor: 4.177

8.  Hepatitis C virus and non-Hodgkin's lymphoma: Findings from the Swiss HIV Cohort Study.

Authors:  S Franceschi; J Polesel; M Rickenbach; L Dal Maso; N M Probst-Hensch; C Fux; M Cavassini; B Hasse; A Kofler; B Ledergerber; P Erb; G M Clifford
Journal:  Br J Cancer       Date:  2006-11-14       Impact factor: 7.640

9.  Cancer risk in persons with HIV/AIDS in India: a review and future directions for research.

Authors:  Robert J Biggar; Anil K Chaturvedi; Kishor Bhatia; Sam M Mbulaiteye
Journal:  Infect Agent Cancer       Date:  2009-03-28       Impact factor: 2.965

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.